{"transactions":[{"id":388382,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":2,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Option Warrant","published_at":"2020-07-13T22:27:21.000Z","date":"2020-07-09","kind":"other","acquired":false,"shares":38979,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the shares are currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.88,"expiration_date":"2020-07-09","underlying":"Common Stock, $0.001 par value","underlying_shares":38979},"source":{"system":"sec-edgar","filing":"0001104659-20-083172","document":"tm2024764-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/14272/000110465920083172/tm2024764-1_4.xml","form_type":"4"}},{"id":388381,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":2,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-13T22:27:21.000Z","date":"2020-07-09","kind":"sale","acquired":false,"shares":2241,"price":102.28,"value":229209.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On July 9, 2020, the Reporting Persons exercised a warrant to purchase 38,979 shares of the Issuer's common stock for $5.88 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,241 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 36,738 shares."}],"balance_after":7008510,"source":{"system":"sec-edgar","filing":"0001104659-20-083172","document":"tm2024764-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000110465920083172/tm2024764-1_4.xml","form_type":"4"}},{"id":388380,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":2,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-13T22:27:21.000Z","date":"2020-07-09","kind":"other","acquired":true,"shares":38979,"price":5.88,"value":229196.52,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company (the \"Reporting Persons\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities."}],"balance_after":7010751,"source":{"system":"sec-edgar","filing":"0001104659-20-083172","document":"tm2024764-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000110465920083172/tm2024764-1_4.xml","form_type":"4"}},{"id":388593,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/","position":1,"cik":"0000816284","reported_name":"CELGENE CORP /DE/","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":2,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-06T21:24:22.000Z","date":"2020-07-01","kind":"purchase","acquired":true,"shares":108108,"price":92.5,"value":9999990.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities."}],"balance_after":6971772,"source":{"system":"sec-edgar","filing":"0001104659-20-081337","document":"tm2024196-2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000110465920081337/tm2024196-2_4.xml","form_type":"4"}},{"id":495847,"issuer":{"id":16805,"kind":"organization","name":"INHIBITEX, INC.","symbol":"INHX"},"owners":[{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":1,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16806,"kind":"organization","name":"Inta Acquisition Corp","position":2,"cik":"0001539753","reported_name":"Inta Acquisition Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001 PER SHARE","published_at":"2012-02-15T21:36:06.000Z","date":"2012-02-13","kind":"other","acquired":true,"shares":3548704,"price":26,"value":92266304.0,"ownership":{"direct":false,"nature":"SEE NOTES"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Inta Acquisition Corporation, a Delaware corporation (\"Purchaser\"), is wholly-owned by Bristol-Myers Squibb Company (\"Parent\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"On January 7, 2012, Inhibitex, Inc. (\"Issuer\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser commenced a cash tender offer to acquire all of the shares of the Issuer's common stock (the \"Offer\") for a purchase price of $26.00 per share in cash."},{"field":"shares","element":"transactionShares","label":"F4","text":"Concurrently with the execution of the Merger Agreement, each of Gabriele Cerrone, Panetta Partners, Ltd., Russell H. Plumb, New Enterprise Associates 10, Limited Partnership, New Enterprise Associates 11, Limited Partnership and Michael James Barrett (each, a \"Stockholder\"), among others, entered into a Tender and Support Agreement with the Issuer, Parent and Purchaser (the \"Support Agreement\").  Pursuant to the Support Agreement, each Stockholder, among other things, elected to exercise such Stockholder's warrants and/or vested options, on a net exercise basis, following the acceptance of the Offer and to transfer those newly-issued Shares to Purchaser.  Collectively, the Stockholders transferred 3,548,704 shares of Common Stock to Purchaser."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares of Common Stock validly tendered and not validly withdrawn collectively with the shares of Common Stock transferred to Purchaser under the Support Agreement represent approximately 96% of the shares of Common Stock outstanding."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Inta Acquisition Corporation, a Delaware corporation (\"Purchaser\"), is wholly-owned by Bristol-Myers Squibb Company (\"Parent\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 7, 2012, Inhibitex, Inc. (\"Issuer\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser commenced a cash tender offer to acquire all of the shares of the Issuer's common stock (the \"Offer\") for a purchase price of $26.00 per share in cash."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"At 12:00 midnight, New York City time, on February 10, 2012, the Offer expired as scheduled.  The Offer was not extended.  Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 81,793,316 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 4,260,705 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Concurrently with the execution of the Merger Agreement, each of Gabriele Cerrone, Panetta Partners, Ltd., Russell H. Plumb, New Enterprise Associates 10, Limited Partnership, New Enterprise Associates 11, Limited Partnership and Michael James Barrett (each, a \"Stockholder\"), among others, entered into a Tender and Support Agreement with the Issuer, Parent and Purchaser (the \"Support Agreement\").  Pursuant to the Support Agreement, each Stockholder, among other things, elected to exercise such Stockholder's warrants and/or vested options, on a net exercise basis, following the acceptance of the Offer and to transfer those newly-issued Shares to Purchaser.  Collectively, the Stockholders transferred 3,548,704 shares of Common Stock to Purchaser."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The shares of Common Stock validly tendered and not validly withdrawn collectively with the shares of Common Stock transferred to Purchaser under the Support Agreement represent approximately 96% of the shares of Common Stock outstanding."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Inta Acquisition Corporation, a Delaware corporation (\"Purchaser\"), is wholly-owned by Bristol-Myers Squibb Company (\"Parent\")."}],"balance_after":85342020,"source":{"system":"sec-edgar","filing":"0001181431-12-009127","document":"rrd334186.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000118143112009127/rrd334186.xml","form_type":"4"}},{"id":495846,"issuer":{"id":16805,"kind":"organization","name":"INHIBITEX, INC.","symbol":"INHX"},"owners":[{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":1,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16806,"kind":"organization","name":"Inta Acquisition Corp","position":2,"cik":"0001539753","reported_name":"Inta Acquisition Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001 PER SHARE","published_at":"2012-02-15T21:36:06.000Z","date":"2012-02-13","kind":"other","acquired":true,"shares":81793316,"price":26,"value":2126626216.0,"ownership":{"direct":false,"nature":"SEE NOTES"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Inta Acquisition Corporation, a Delaware corporation (\"Purchaser\"), is wholly-owned by Bristol-Myers Squibb Company (\"Parent\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"On January 7, 2012, Inhibitex, Inc. (\"Issuer\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser commenced a cash tender offer to acquire all of the shares of the Issuer's common stock (the \"Offer\") for a purchase price of $26.00 per share in cash."},{"field":"shares","element":"transactionShares","label":"F3","text":"At 12:00 midnight, New York City time, on February 10, 2012, the Offer expired as scheduled.  The Offer was not extended.  Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 81,793,316 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 4,260,705 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares of Common Stock validly tendered and not validly withdrawn collectively with the shares of Common Stock transferred to Purchaser under the Support Agreement represent approximately 96% of the shares of Common Stock outstanding."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Inta Acquisition Corporation, a Delaware corporation (\"Purchaser\"), is wholly-owned by Bristol-Myers Squibb Company (\"Parent\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 7, 2012, Inhibitex, Inc. (\"Issuer\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser commenced a cash tender offer to acquire all of the shares of the Issuer's common stock (the \"Offer\") for a purchase price of $26.00 per share in cash."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"At 12:00 midnight, New York City time, on February 10, 2012, the Offer expired as scheduled.  The Offer was not extended.  Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 81,793,316 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 4,260,705 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Concurrently with the execution of the Merger Agreement, each of Gabriele Cerrone, Panetta Partners, Ltd., Russell H. Plumb, New Enterprise Associates 10, Limited Partnership, New Enterprise Associates 11, Limited Partnership and Michael James Barrett (each, a \"Stockholder\"), among others, entered into a Tender and Support Agreement with the Issuer, Parent and Purchaser (the \"Support Agreement\").  Pursuant to the Support Agreement, each Stockholder, among other things, elected to exercise such Stockholder's warrants and/or vested options, on a net exercise basis, following the acceptance of the Offer and to transfer those newly-issued Shares to Purchaser.  Collectively, the Stockholders transferred 3,548,704 shares of Common Stock to Purchaser."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The shares of Common Stock validly tendered and not validly withdrawn collectively with the shares of Common Stock transferred to Purchaser under the Support Agreement represent approximately 96% of the shares of Common Stock outstanding."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Inta Acquisition Corporation, a Delaware corporation (\"Purchaser\"), is wholly-owned by Bristol-Myers Squibb Company (\"Parent\")."}],"balance_after":85342020,"source":{"system":"sec-edgar","filing":"0001181431-12-009127","document":"rrd334186.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000118143112009127/rrd334186.xml","form_type":"4"}},{"id":514405,"issuer":{"id":16945,"kind":"organization","name":"ZYMOGENETICS INC","symbol":"ZGEN"},"owners":[{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":1,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16946,"kind":"organization","name":"Zeus Acquisition Corp","position":2,"cik":"0001501223","reported_name":"Zeus Acquisition Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2010-10-08T21:12:19.000Z","date":"2010-10-08","kind":"other","acquired":true,"shares":82605529,"price":9.75,"value":805403907.75,"ownership":{"direct":false,"nature":"See note"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Zeus Acquisition Corporation, a Washington corporation (\"Purchaser\"), is wholly-owned by Bristol-Myers Squibb Company (\"Parent\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"On September 7, 2010, ZymoGenetics, Inc. entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser has commenced a cash tender offer to acquire all of the shares of the Issuer's Common Stock (the \"Offer\") for a purchase price of $9.75 per share in cash (the \"Offer Price\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"At 12:00 midnight, New York City time, on October 7, 2010, the Offer expired as scheduled. The Offer was not extended.  Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 82,605,529 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 1,501,981 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. The shares of Common Stock validly tendered and not validly withdrawn represent approximately 94.9% of the shares of Common Stock outstanding."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Zeus Acquisition Corporation, a Washington corporation (\"Purchaser\"), is wholly-owned by Bristol-Myers Squibb Company (\"Parent\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 7, 2010, ZymoGenetics, Inc. entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser has commenced a cash tender offer to acquire all of the shares of the Issuer's Common Stock (the \"Offer\") for a purchase price of $9.75 per share in cash (the \"Offer Price\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"At 12:00 midnight, New York City time, on October 7, 2010, the Offer expired as scheduled. The Offer was not extended.  Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 82,605,529 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 1,501,981 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. The shares of Common Stock validly tendered and not validly withdrawn represent approximately 94.9% of the shares of Common Stock outstanding."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Zeus Acquisition Corporation, a Washington corporation (\"Purchaser\"), is wholly-owned by Bristol-Myers Squibb Company (\"Parent\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"On September 7, 2010, ZymoGenetics, Inc. entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser has commenced a cash tender offer to acquire all of the shares of the Issuer's Common Stock (the \"Offer\") for a purchase price of $9.75 per share in cash (the \"Offer Price\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"At 12:00 midnight, New York City time, on October 7, 2010, the Offer expired as scheduled. The Offer was not extended.  Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 82,605,529 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 1,501,981 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. The shares of Common Stock validly tendered and not validly withdrawn represent approximately 94.9% of the shares of Common Stock outstanding."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Zeus Acquisition Corporation, a Washington corporation (\"Purchaser\"), is wholly-owned by Bristol-Myers Squibb Company (\"Parent\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"On September 7, 2010, ZymoGenetics, Inc. entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser has commenced a cash tender offer to acquire all of the shares of the Issuer's Common Stock (the \"Offer\") for a purchase price of $9.75 per share in cash (the \"Offer Price\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"At 12:00 midnight, New York City time, on October 7, 2010, the Offer expired as scheduled. The Offer was not extended.  Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 82,605,529 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 1,501,981 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. The shares of Common Stock validly tendered and not validly withdrawn represent approximately 94.9% of the shares of Common Stock outstanding."}],"balance_after":82605529,"source":{"system":"sec-edgar","filing":"0001181431-10-050368","document":"rrd288286.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000118143110050368/rrd288286.xml","form_type":"4"}},{"id":525292,"issuer":{"id":17020,"kind":"organization","name":"Mead Johnson Nutrition Co","symbol":"MJN"},"owners":[{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":1,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Common Stock","published_at":"2009-12-22T22:15:01.000Z","date":"2009-12-18","kind":"exercise","acquired":false,"shares":127655429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis and had no exercise or conversion price or expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Prior to November 13, 2009, the reported securities were owned directly by E.R. Squibb & Sons, L.L.C. (\"ERS\"), which is a wholly-owned subsidiary of BMS. On November 13, 2009, ERS distributed the reported securities to BMS."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":127655429},"source":{"system":"sec-edgar","filing":"0001181431-09-058294","document":"rrd260711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/14272/000118143109058294/rrd260711.xml","form_type":"4"}},{"id":525291,"issuer":{"id":17020,"kind":"organization","name":"Mead Johnson Nutrition Co","symbol":"MJN"},"owners":[{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":1,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2009-12-22T22:15:01.000Z","date":"2009-12-18","kind":"other","acquired":false,"shares":170000000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Bristol-Myers Squibb Company (\"BMS\") disposed of 170,000,000 shares of Class A Common Stock in exchange for 269,285,601 shares of BMS common stock pursuant to a registered exchange offer to BMS common stockholders. The final exchange ratio for the exchange offer was 0.6313 shares of Class A\nCommon Stock per share of BMS common stock accepted in the exchange offer. As a result of the exchange offer, BMS has disposed of its entire equity interest in the Issuer. The closing price of BMS common stock on the New York Stock Exchange on December 18, 2009 was $25.78."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001181431-09-058294","document":"rrd260711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000118143109058294/rrd260711.xml","form_type":"4"}},{"id":525290,"issuer":{"id":17020,"kind":"organization","name":"Mead Johnson Nutrition Co","symbol":"MJN"},"owners":[{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":1,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2009-12-22T22:15:01.000Z","date":"2009-12-18","kind":"exercise","acquired":true,"shares":127655429,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price."}],"balance_after":170000000,"source":{"system":"sec-edgar","filing":"0001181431-09-058294","document":"rrd260711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000118143109058294/rrd260711.xml","form_type":"4"}},{"id":660502,"issuer":{"id":13652,"kind":"organization","name":"ANESIVA, INC.","symbol":"ANSV"},"owners":[{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":1,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Series D Preferred Stock","published_at":"2004-02-18T23:52:09.000Z","date":"2004-02-18","kind":"exercise","acquired":false,"shares":2079002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's preferred stock automatically converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2004-02-11","underlying":"Common Stock","underlying_shares":2079002},"source":{"system":"sec-edgar","filing":"0001104659-04-005036","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/14272/000110465904005036/a4.xml","form_type":"4"}},{"id":660501,"issuer":{"id":13652,"kind":"organization","name":"ANESIVA, INC.","symbol":"ANSV"},"owners":[{"id":1662,"kind":"organization","name":"BRISTOL MYERS SQUIBB CO","symbol":"BMY","position":1,"cik":"0000014272","reported_name":"BRISTOL MYERS SQUIBB CO","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Common Stock","published_at":"2004-02-18T23:52:09.000Z","date":"2004-02-18","kind":"exercise","acquired":true,"shares":2079002,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2079002,"source":{"system":"sec-edgar","filing":"0001104659-04-005036","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/14272/000110465904005036/a4.xml","form_type":"4"}}]}